associated with the spread of an IncF plasmid carrying Tn4401d. 6 Molecular analyses revealed that E. coli #40336 belonged to the ST167 phylogroup A, of the ST10 complex, also reported in US hospitals to spread bla KPC genes.
7
To the best of our knowledge, this is the first report of a KPCproducing Enterobacteriaceae isolated from filter-feeding molluscs, and more globally from a food product bought at a retail market, thereby posing a potential direct threat to public health. Considering the absence of carbapenem use in animals and the global epidemiology of bla KPC plasmids and KPC-producing E. coli clones, this isolate is most likely of human origin. The mussels sampled here were grown in an area receiving hospital effluents, which is consistent with other data on KPC-producing K. pneumoniae reported from wastewater in Austria and Brazil. 8, 9 Together with the very recent finding of KPC-2 in clinical isolates in Tunisia, 10, 11 our data also support the spread of KPC-3 in humans in this country. Such an MDR KPC-producing E. coli strain in M. galloprovincialis bought at a retail market suggests that other filterfeeding mollusc species may be likely to concentrate carbapenem-resistant Enterobacteriaceae from the human reservoir. The question of whether the food chain has a role in transferring MDR organisms to humans has been raised repeatedly. Here we have shown that molluscs are likely to be an intermediate step disseminating carbapenem-hydrolysing b-lactamases most probably from hospital activities, and these enzymes could further spread back to the human community through food intake or handling. Sir, Polymyxins are the last resort for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae (CRE). In November 2015, Liu et al.
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1 described for the first time a colistin resistance mechanism mediated by a new gene (mcr-1), which was present in a transferable plasmid. Since then, several reports have indicated that mcr-1 has silently spread worldwide since 1980.
2 Of particular concern is the dissemination of the mcr-1 gene in CRE, potentially leading to pan-drug-resistant isolates. There are only scattered reports of co-occurrence of bla KPC and mcr-1 genes in the same isolate. 3, 4 This study evaluates the characteristics of the first clinical isolate of Escherichia coli harbouring both mcr-1 and bla KPC-2 genes in Latin America.
Among 1883 CRE clinical isolates screened, 1 KPC-2-producing E. coli was also positive for the mcr-1 gene (isolate 3431F). This isolate was obtained from a rectal swab of a patient hospitalized, in September 2014, at an emergency room of a general hospital in Porto Alegre city, Rio Grande do Sul, the southernmost Brazilian state.
The bla KPC-2 /mcr-1-positive clinical isolate carried at least two distinct plasmids, which were successfully transferred to E. coli J53 by conjugation. Two transconjugants were further evaluated: the transconjugant 3431FT1, which carried only one plasmid and was positive for mcr-1, and the transconjugant 3431FT2, which carried two plasmids and was positive for both mcr-1 and bla KPC-2 ( Table 1 ). The 3431F clinical isolate presented high MICs (32 mg/L) of the carbapenems and lowlevel resistance to colistin (MIC 4 mg/L); the transconjugants 3431FT1 and 3431FT2 presented significant increases in the MIC of colistin in comparison with E. coli J53 and the transconjugant 3431FT2 also presented increased MICs of the carbapenems ( Table 1) .
The assembled WGS of the clinical isolate 3431F produced 67 scaffolds, which resulted in an estimated draft genome 4891834 bp in length, with a G ! C content of 50.7% and a total of 4819 genomic features. The in silico analyses of the data indicated that E. coli 3431F belongs to ST744, an E. coli lineage usually associated with resistance genes, including a clinical isolate harbouring mcr-1 and ESBL genes in Denmark. 5 The WGS data confirmed the presence of the bla KPC-2 and mcr-1 genes, as well as several other resistance genes, such as genes encoding aminoglycoside-modifying enzymes [strA, strB and aph(3 0 )-la], a b-lactamase-encoding gene (bla TEM-1 ) and genes related to resistance to macrolides [mph(A) and erm(42)], phenicols (floR and catA1), sulphonamides (sul2) and tetracycline [tet(A) and tet(B)].
The in silico analyses also allowed identification of the following plasmid incompatibility types in the 3431F isolate: IncN, IncFIB, IncQ1 and IncX4. Detailed analyses indicated that bla KPC-2 was located in the IncFIB plasmid and mcr-1 was located in the IncX4 plasmid. bla KPC-2 was located on a Tn4401 transposon, isoform b. The scaffold bearing bla KPC-2 was 85492 bp in length and no other resistance gene was found in this scaffold.
Detailed analysis of the scaffold bearing the mcr-1 gene suggested that it was a complete plasmid (a possible circular molecule 33511 bp in length). For this reason, primers were designed to close the gaps in this scaffold and PCRs, followed by Sanger sequencing, confirmed the circular plasmid molecule. This plasmid, which was termed pMCR1poa (GenBank MTJV00000000), presented .99% overall identity as compared with pICBEC72H (GenBank CP015977), 6 pESTMCR (GenBank KU743383), 7 pMCR1.2-IT (GenBank KX236309) 3 and pMCR1-IncX4 (GenBank KU761327), 8 and 96% identity with pAf48 (GenBank KX032520).
9 pMCR1poa harbours an ISApl1 insertion and a pap2 gene upstream and downstream of the mcr-1 gene, respectively, as also observed in other mcr-1-bearing plasmids described in other countries. 1, 3, [6] [7] [8] [9] The IncX4-type plasmid carrying the mcr-1 gene, identified in this study, was previously described in several isolates carrying the mcr-1 gene, including a clinical isolate obtained from a hospitalized patient in north-eastern Brazil. 6 Isolates of E. coli harbouring the IncX4-type plasmid containing the mcr-1 gene have MICs were determined by broth microdilution, except those of ertapenem, imipenem and meropenem, which were determined by Etest.
also been identified in poultry from southern Brazil by our group (data not shown). In summary, we report the occurrence of the mcr-1 gene in a bla KPC-2 -positive E. coli clinical isolate from Brazil. To the best of our knowledge this is the first report of a clinical isolate with both genes in Latin America. In addition, our findings underscore the broad intercontinental distribution of the IncX4 mcr-1-bearing plasmid. Considering the low prevalence of the mcr-1 gene among clinical isolates of CRE observed in our study, it seems that while carbapenem resistance is high, plasmid-mediated colistin resistance is still rare and sporadic among CRE clinical isolates.
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